Immunizations Flashcards
How often should the Influenza vaccine be given and indications to receiving the dose
Every year. 6 months and older.
TD
Substitute 1 time dose of TD for TDAP and then administer TD every year. All pregnant women need TDAP every pregnancy @ 27-36 gestation. Unvaccinated adults: Administer first dose at least 4 weeks apart and 3rd dose 6-12 months after the 2nd dose
Varicella
2 doses. Do not administer in pregnant women and immunocompromised individual. It should be given to MSM, kidney, ESRD, heart disease, chronic lung dis., Alcholism, renal failure, asplenia, liver dis, DM, health care professionals
HPV
3 doses. Females 11 or 12. 13-21. No previous vaccines 22-26
Zoster
60 +. Do not give if pregnant of immunocompromised. Although FDA states that you could get it at 50, ACIP recommends 60 plus.
MMR
1-2 doses If born before 1957 consider immune, Avoid during pregnancy and in immunocompromised people. MSM, Kidney, ESRD, heart, chronic dis, lung, Chronic ETOH, liver, DM health care workers
PCV13
Adults aged 19 years or older with immunocompromising conditions
(including chronic renal failure and nephrotic syndrome), functional or
anatomic asplenia, cerebrospinal fluid leaks, or cochlear implants who have not previously received PCV13 or PPSV23 should receive a single
dose of PCV13 followed by a dose of PPSV23 at least 8 weeks later.
• Adults aged 19 years or older with the aforementioned conditions who have previously received 1 or more doses of PPSV23 should receive a dose of PCV13 one or more years after the last PPSV23 dose was received. For
adults who require additional doses of PPSV23, the first such dose should be given no sooner than 8 weeks after PCV13 and at least 5 years after the
most recent dose of PPSV23.
• When indicated, PCV13 should be administered to patients who are
uncertain of their vaccination status history and have no record of previous
vaccination.
Although PCV13 is licensed by the U.S. Food and Drug Administration for use among and can be administered to persons aged 50 years or older,
ACIP recommends PCV13 for adults aged 19 years or older with the specific medical conditions noted above. 9. Pneumococcal polysaccharide (PPSV23
PPSV23
Vaccinate all persons with the following indications:
— all adults aged 65 years or older; — adults younger than 65 years with chronic lung disease (including chronic obstructive pulmonary disease, emphysema, and asthma), chronic cardiovascular diseases, diabetes mellitus, chronic renal
failure, nephrotic syndrome, chronic liver disease (including cirrhosis), alcoholism, cochlear implants, cerebrospinal fluid leaks, immunocom- promising conditions, and functional or anatomic asplenia (e.g., sickle cell disease and other hemoglobinopathies, congenital or acquired
asplenia, splenic dysfunction, or splenectomy [if elective splenectomy is planned, vaccinate at least 2 weeks before surgery]); — residents of nursing homes or long-term care facilities; and — adults who smoke cigarettes. • Persons with immunocompromising conditions and other selected conditions are recommended to receive PCV13 and PPSV23 vaccines. See
footnote 8 for information on timing of PCV13 and PPSV23 vaccinations.
• Persons with asymptomatic or symptomatic HIV infection should be
vaccinated as soon as possible after their diagnosis.
• When cancer chemotherapy or other immunosuppressive therapy is
being considered, the interval between vaccination and initiation of
immunosuppressive therapy should be at least 2 weeks. Vaccination during chemotherapy or radiation therapy should be avoided.
• Routine use of PPSV23 vaccine is not recommended for American Indians/Alaska Natives or other persons younger than 65 years unless they have underlying medical conditions that are PPSV23 indications. However,
public health authorities may consider recommending PPSV23 for American Indians/Alaska Natives who are living in areas where the risk for invasive pneumococcal disease is increased.
• When indicated, PPSV23 vaccine should be administered to patients who are uncertain of their vaccination status and have no record of vaccination.
Revaccination with PPSV23
One-time revaccination 5 years after the first dose of PPSV23 is recommended for persons aged 19 through 64 years with chronic renal failure or nephrotic syndrome, functional or anatomic asplenia (e.g., sickle cell disease or splenectomy), or immunocompromising conditions.
• Persons who received 1 or 2 doses of PPSV23 before age 65 years for any indication should receive another dose of the vaccine at age 65 years or later if at least 5 years have passed since their previous dose.
• No further doses of PPSV23 are needed for persons vaccinated with
PPSV23 at or after age 65 years.
Meningocococcal
Administer 2 doses of quadrivalent meningococcal conjugate vaccine (MenACWY [Menactra, Menveo]) at least 2 months apart to adults of all ages with functional asplenia or persistent complement component deficiencies. HIV infection is not an indication for routine vaccination with MenACWY. If an HIV-infected person of any age is vaccinated, 2 doses of MenACWY should be administered at least 2 months apart.
First-year college students up through age 21 years who are living in residence halls should be vaccinated if they have not received a dose on
or after their 16th birthday.
Revaccination with MenACWY every 5 years is recommended for adults previously vaccinated with MenACWY or MPSV4 who remain at increased
risk for infection (e.g., adults with anatomic or functional asplenia, persistent complement component deficiencies, or microbiologists).
Hep A
Vaccinate anyone who desires to have Hep A vaccine.
MSM and persons who are using illicit drugs.
Persons working with HV infected persons and people who work in labs.
Persons with chronic liver diseases and persons who receive clotting factor concentrates
People traveling to countries that are endemic to Hep A.
Unvaccinated persons
Dose 0 and 6-12 months
Hep B
Anyone seeking protection from Hep B infection. Sexually active persons with more than 1 sexual partner during the previous 6 months….persons who are not in a monogamous relationship. Health care personel people with DM, people younger than 60 yrs old. Dialysis pts, chronic liver dis, ESRD, persons in correctional facilities.
Doses 0, 1, 6 months. If pts do not come back in a timely fashion the series should be continued not restarted.
HIB
One dose of Hib vaccine should be administered to persons who have functional or anatomic asplenia or sickle cell disease or are undergoing
elective splenectomy if they have not previously received Hib vaccine.
Hib vaccination 14 or more days before splenectomy is suggested.
• Recipients of a hematopoietic stem cell transplant should be vaccinated with a 3-dose regimen 6 to 12 months after a successful transplant, regardless of vaccination history; at least 4 weeks should separate doses.
• Hib vaccine is not recommended for adults with HIV infection since their risk for Hib infection is low.
